Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4103000 | 0.92 | GPR119 (0.53) | GPR119KDM4EPKMCSF1R | |
| SCHEMBL4106514 | 0.86 | GPR119 (0.52) | GPR119KDM4EPKM | |
| SCHEMBL4099317 | 0.85 | GPR119 (0.55) | GPR119 | |
| SCHEMBL4096462 | 0.85 | GPR119 (0.44) | GPR119KDM4EPKMCSF1RKDR | |
| SCHEMBL386308 | 0.83 | GPR119 (0.47) | GPR119KDM4EPKMFAAH | |
| SCHEMBL1575131 | 0.81 | GPR119 (0.58) | GPR119KDM4EPKM | |
| SCHEMBL391544 | 0.79 | GPR119 (0.47) | GPR119FAAH | |
| SCHEMBL386426 | 0.78 | GPR119 (0.48) | GPR119FAAH | |
| SCHEMBL4104843 | 0.77 | GPR119 (0.54) | GPR119 | |
| SCHEMBL6011556 | 0.77 | GPR119 (0.62) | GPR119KDM4EPKMFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221644-A1 | Gpcr Agonists | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221644-A1 | Gpcr Agonists | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221644-A1 | Gpcr Agonists | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| EP-1907384-A2 | GPCR AGONISTS | Prosidion Limited (GB) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007003961-A2 | GPCR AGONISTS | PROSIDION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007003961-A2 | GPCR AGONISTS | PROSIDION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221644-A1 | Gpcr Agonists | GPR119, GCGR, GPR27 | GPR119 1/4885KDM4E 3925/4885PKM 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.